Report Scope & Overview:
The Epilepsy Surgery Market Size was valued at USD 980 million in 2022 and is expected to reach USD 1483.5 million by 2030 and grow at a CAGR of 5.32% over the forecast period 2023-2030.
Epilepsy surgery is a neurosurgical operation that involves treating the brain areas involved in seizures. The technique is performed to lessen or eliminate the risk of seizures.
To get more information on Epilepsy Surgery Market - Request Sample Report
The growing frequency of neurological illnesses, which has resulted in substantial R&D on epilepsy treatment devices, as well as an increase in cases of brain injuries due to car accidents, are driving the expansion of the epilepsy surgery market. Furthermore, advancements in robot-assisted surgery and an increase in the geriatric population are expected to boost market growth. However, the dangers involved with epilepsy surgery may stifle market expansion.
MARKET DYNAMICS:
KEY DRIVERS:
The development of the product involves significant R&D spending, which enhances R&D costs.
Any industry is significantly reliant on distribution. In this market, intermediaries, direct selling, and other methods of distribution are used.
RESTRAINTS:
The risks associated with epilepsy surgery, on the other hand, may hinder market growth.
The selection of a control or comparison condition, as well as patient heterogeneity, are critical and challenging aspects of neurosurgical equipment clinical studies.
OPPORTUNITY:
Collaboration with research institutes to enable market entrants to gain access to global marketplaces
The expanding senior population prone to seizure diseases, and government attempts to conduct epilepsy surgery research projects
IMPACT OF COVID-19:
The COVID-19 epidemic has disrupted the whole value chain in the epilepsy surgery sector, from raw material sourcing through manufacturing, packaging, and distribution. For the time being, the impact appears to be minor because several manufacturers have sufficient raw materials and end-product stock. If the pandemic continues and trade restrictions are tightened, the damage is expected to worsen.
Except in life-threatening situations, most regular surgical procedures were advised to be postponed. One such category was patients with drug-resistant epilepsy. According to a study conducted by three tertiary care epileptic centres in Spain and Italy, only 14 persons with epilepsy tested positive for the COVID-19 in August 2020.
The COVID-19 pandemic has had a number of consequences for people with epilepsy (PWE), including restrictions on in-person contact and neurophysiological tests. Members of the American Epilepsy Society were polled between April 30 and June 14, 2020, to better understand the epidemic's impact on PWE. In PWE with COVID-19, approximately 17% of respondents reported a rise in seizure frequency, whereas none reported an improvement. In this poll, the most important constraints experienced by PWE were a lack of access to healthcare facilities due to closure and limits on elective care. Approximately 44 percent of respondents noted epilepsy medication shortages.
A little piece of the brain is removed during resective surgery. The surgeon removes brain tissues from the area of the brain where seizures occur, which is frequently the location of a tumour, brain damage, or abnormality. It is the most commonly performed epilepsy surgery. Around 70% of persons who have temporal lobe surgery say that the procedure prevents their seizures; additionally, 20% report a reduction in the frequency of seizures. Despite receiving an acceptable dose of antiepileptic medication for one year, epilepsy surgery is recommended in 30% to 40% of individuals with refractory seizure disorders.
LITT is a minimally invasive treatment for drug-resistant epilepsy or seizures that do not respond to medication. LITT may help certain people who have focal seizures that originate in a single area of the brain. LITT surgery typically takes three to four hours. The development of MRI-guided LITT systems for the ablation of neurological soft tissue.
For surgical therapy of epilepsy, lesinectomy, repeated subpial transections, hemispherectomy and hemispherectomy, corpus callosotomy, stereotactic radiosurgery, and other treatments are available. Another therapeutic option for epilepsy is the use of medical equipment such as neurostimulation device implantations.
End-user hospitals and clinics dominate the epilepsy surgery market. This share is mostly due to an increase in the number of people being diagnosed with epilepsy and having epilepsy surgical treatments. Patients frequently choose to be treated in a hospital because advanced and comprehensive therapies are accessible. Clinics are also medical care centres that treat people with epilepsy.. Europe, the Americas, and developing countries such as India, China, and Russia have the most hospitals giving treatment for this disease.
Specialized epilepsy centres provide normal care to those who have seizures or epilepsy, as well as thorough diagnosis and treatment services to people who have uncontrolled seizures. Patients of various ages can receive thorough therapy at the epilepsy facility. Medication, vagus nerve stimulation, and the ketogenic diet are among the treatment options available at speciality clinics to eliminate or lessen the frequency and intensity of seizures in children and adults.
Electroencephalograms, a medical test used to monitor the electrical activity of the brain, are performed in diagnostic and neurology centres to determine the severity of seizures. Patients are assisted with surgical operations by neurologists, neurosurgeons, radiologists, neuropsychologists, and other healthcare specialists.
VALUE CHAIN ANALYSIS:
The epilepsy surgery market is expected to develop significantly over the forecast period, owing to factors such as rapid technical advancements in device technology, improved medical facilities, and a rising patient pool in need of surgical treatment. The value chain analysis for the epilepsy surgery market includes four primary components, beginning with research and product development and progressing to product manufacturing, distribution, and marketing and sales.
High R&D investments are required for product development, which raises R&D spending. Furthermore, the product designs are complete, and the manufacturing process has begun. Some of the product development procedures used in component production are sometimes outsourced. Distribution is an essential component of any industry. Distribution in this sector includes intermediaries, direct selling, and others. Hospitals, clinics, ambulatory surgical center, and specialized centre are the primary purchasers of the products.
KEY MARKET SEGMENTS:
By Procedure Type
Resective Surgery
Laser Interstitial Thermal Therapy (LITT)
Others
By End User
Hospitals & Clinics
Specialty Centers
Others
.png)
Need any customization research on Epilepsy Surgery Market - Enquiry Now
REGIONAL ANALYSIS:
The Americas dominated the epilepsy surgery market due to a number of factors, including the availability of well-established healthcare facilities, the high prevalence of neurological disorders, and the rising frequency of epilepsy. Europe has evolved as a major epilepsy surgical market due to increased investment in research and development, the launch of successful epileptic medications, and a high prevalence of epilepsy. The region has significant growth potential, which will aid the epilepsy surgery market in the approaching years.
The Asia-Pacific area offers lucrative potential for epilepsy surgery companies due to the existence of a large senior population, governmental measures to improve the healthcare sector, an increase in research and development activities, and an increase in epilepsy prevalence in the region.
Epilepsy affects a significant proportion of the elderly population.
The Middle East and Africa epilepsy surgery market is divided into three major regions: the Middle East, Africa, and Latin America. The epilepsy surgery market is being pushed by factors such as increased epilepsy incidence, an increase in the older population, and rising disposable income in the region.
REGIONAL COVERAGE:
North America
USA
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Rest of Europe
Asia-Pacific
Japan
south Korea
China
India
Australia
Rest of Asia-Pacific
The Middle East & Africa
Israel
UAE
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
KEY PLAYERS:
Major players are The key players are Auris Health, Inc., Intuitive Surgical, Livanova Plc, Monteris Medical, CMR Surgical, Natus Medical Incorporated, Stryker, Zimmer Biomet Holdings Inc., Medtronic Plc, Cephalon, Inc. & Other Players
| Report Attributes | Details |
| Market Size in 2022 | US$ 980 Million |
| Market Size by 2030 | US$ 1483.5 Million |
| CAGR | CAGR of 5.35% From 2023 to 2030 |
| Base Year | 2022 |
| Forecast Period | 2023-2030 |
| Historical Data | 2020-2021 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By End User (Hospitals & Clinics, Specialty Centers) • By Procedure Type (Resective Surgery, Laser Interstitial Thermal Therapy) |
| Regional Analysis/Coverage | North America (USA, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (Japan, South Korea, China, India, Australia, Rest of Asia-Pacific), The Middle East & Africa (Israel, UAE, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Auris Health, Inc., Intuitive Surgical, Livanova Plc, Monteris Medical, CMR Surgical, Natus Medical Incorporated, Stryker, Zimmer Biomet Holdings Inc., Medtronic Plc, Cephalon, Inc. |
| Key Drivers | • The development of the product involves significant R&D spending, which enhances R&D costs. |
| Market Opportunities | • Collaboration with research institutes to enable market entrants to gain access to global marketplaces |
Ans: The Epilepsy Surgery Market is to grow at a CAGR of 5.32% over the forecast period 2023-2030.
Ans: The Epilepsy Surgery Market size was valued at US$ 980 Mn in 2022.
The development of the product involves significant R&D spending, which enhances R&D costs.
Any industry is significantly reliant on distribution. In this market, intermediaries, direct selling, and other methods of distribution are used.
Collaboration with research institutes to enable market entrants to gain access to global marketplaces
The expanding senior population prone to seizure diseases, and government attempts to conduct epilepsy surgery research projects
Ans: forecast period of Epilepsy Surgery Market is 2023-2030.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 COVID 19 Impact Analysis
4.2 Impact of the Ukraine- Russia war
4.3 Impact of ongoing Recession
4.3.1 Introduction
4.3.2 Impact on major economies
4.3.2.1 US
4.3.2.2 Canada
4.3.2.3 Germany
4.3.2.4 France
4.3.2.5 United Kingdom
4.3.2.6 China
4.3.2.7 Japan
4.3.2.8 South Korea
4.3.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8.Epilepsy Surgery Market, by Procedure Type
8.1 Resective Surgery
8.2 Laser Interstitial Thermal Therapy (LITT)
8.3 Others
9.Epilepsy Surgery Market, by End User
9.1 Hospitals & Clinics
9.2 Specialty Centers
9.3 Others
10. Regional Analysis
10.1 Introduction
10.2 North America
10.2.1 USA
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Italy
10.3.5 Spain
10.3.6 The Netherlands
10.3.7 Rest of Europe
10.4 Asia-Pacific
10.4.1 Japan
10.4.2 South Korea
10.4.3 China
10.4.4 India
10.4.5 Australia
10.4.6 Rest of Asia-Pacific
10.5 The Middle East & Africa
10.5.1 Israel
10.5.2 UAE
10.5.3 South Africa
10.5.4 Rest
10.6 Latin America
10.6.1 Brazil
10.6.2 Argentina
10.6.3 Rest of Latin America
11.Company Profiles
11.1 Auris Health, Inc.
11.1.1 Financial
11.1.2 Products/ Services Offered
11.1.3 SWOT Analysis
11.1.4 The SNS view
11.2 Intuitive Surgical
11.3 Livanova Plc
11.4 Monteris Medical
11.5 CMR Surgical
11.6 Natus Medical Incorporated
11.7 Stryker
11.8 Zimmer Biomet Holdings Inc.
11.9 Medtronic Plc
11.10 Cephalon, Inc.
12. Competitive Landscape
12.1 Competitive Benchmarking
12.2 Market Share Analysis
12.3 Recent Developments
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Healthcare EDI Market Size was valued at USD 3.81 billion in 2022, and is expected to reach USD 7.53 billion by 2030, and grow at a CAGR of 8.9% over the forecast period 2023-2030.
The Cardiovascular Information System Market Size was valued at USD 8.20 billion in 2022 and is expected to reach USD 14.96 billion by 2030, and grow at a CAGR of 7.8% over the forecast period 2023-2030.
The Breast implants Market Size was valued at USD 3.37 billion in 2022 and is expected to reach USD 5.79 billion by 2030, and grow at a CAGR of 7% over the forecast period 2023-2030.
In 2022, The Anti-Inflammatory Drugs Market size amounted to USD 112.34 Billion & is estimated to reach USD 232.19 Billion by 2030 and increase at a compound annual growth rate of 9.5% between 2023 and 2030.
The Dual Chamber Prefilled Syringes Market size was USD 154.21 million in 2022 and is expected to Reach USD 268.56 million by 2030 and grow at a CAGR of 7.08 % over the forecast period of 2023-2030.
The Human Papillomavirus (HPV) Vaccine Market size was USD 4.12 Billion in 2022 and is expected to Reach USD 10.64 Billion by 2030 and grow at a CAGR of 12.6% over the forecast period of 2023-2030.
Hi! Click one of our member below to chat on Phone
© 2023 All Rights Reserved by SNS Insider Pvt Ltd
